Highlights of This Issue 2721

SPECIAL FEATURES

CCR Translations

2723 Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Michael Pollak
See article p. 2905

Molecular Pathways

2726 Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.B. Seftor, and Mary J.C. Hendrix

CCR Focus

2734 Progress in Pediatric Cancer
Susan E. Bates
2735 Genetically InFormed Therapies—A "GIFT" for Children with Cancer
Carol J. Thiele and Susan L. Cohn
2740 Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthay, Rani E. George, and Alice L. Yu
2754 Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy
Mignon L. Loh and Charles G. Mullighan
2768 Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Elizabeth R. Lawlor and Carol J. Thiele
2780 The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp
2791 Using Germline Genomics to Individualize Pediatric Cancer Treatments
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

Perspective

2801 Disrupting the Networks of Cancer
Daniel F. Camacho and Kenneth J. Pienta

HUMAN CANCER BIOLOGY

2817 Suppression of Skeletal Muscle Turnover in Cancer Cachexia: Evidence from the Transcriptome in Sequential Human Muscle Biopsies

2828 MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

Review

2809 Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?
Peter H. O'Donnell and Walter M. Stadler
Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients
Daniela Speisky, Aurélie Duces, Pascal Hammel, Vinciane Rebour, Alain Sauvanet, Stéphane Richard, Pierre Bedossa, Michel Vidaud, Arnaud Murat, Patricia Niccoli, Jean-Yves Souzaee, Philippe Ruszniewski, and Anne Couvelard for the GTE Group (Groupe d'Etude des Tumeurs Endocrines)

CANCER THERAPY: CLINICAL
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Navid Sadeghi, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li
See commentary p. 2723

Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron
Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O'Mahony, Peter Donachie, and Julian Howell

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Jennifer Wheater, Apostolia M. Tsibberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paual, Siqiang Fu, Stacy Moulder, Betzlay Stephen, Sijin Wen, and Razelle Kurzrock

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy

IMAGING, DIAGNOSIS, PROGNOSIS
Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto, Tom Böhling, Heli Kavola, Virve Koljonen, Marko Salmi, Sirpa Jalkanen, and Heikki Joensuu

Global Methylation Profiling for Risk Prediction of Prostate Cancer
Sawwati Mahapatra, Eric W. Kleee, Charles Y.F. Young, Zhifu Sun, Rafael E. Jimenez, George G. Kleee, Donald J. Tindall, and Krishna Vanaja Donkena

Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinicopathologic Features of Prostate Cancer
Ken Kron, Liyang Liu, Dominique Trudel, Vaijayanti Pethe, John Trachtenberg, Neil Fleshner, Bharati Bapat, and Theodorus van der Kwast

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

2964 Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer
Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudia Coco, Giovanni Scambia, Shohreh Shahabi, and Cristiano Ferlini

2976 An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Florence de Fraipont, Guénaelle Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

ABOUT THE COVER

Methylation of the tumor suppressor gene Ras association domain family 1A (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluo red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.